Synonym
Flupirtine; Katadolon; Flupirtine Maleate Salt
IUPAC/Chemical Name
ethyl (2-amino-6-((4-fluorobenzyl)amino)pyridin-3-yl)carbamate maleate
InChi Key
DPYIXBFZUMCMJM-BTJKTKAUSA-N
InChi Code
InChI=1S/C15H17FN4O2.C4H4O4/c1-2-22-15(21)19-12-7-8-13(20-14(12)17)18-9-10-3-5-11(16)6-4-10;5-3(6)1-2-4(7)8/h3-8H,2,9H2,1H3,(H,19,21)(H3,17,18,20);1-2H,(H,5,6)(H,7,8)/b;2-1-
SMILES Code
O=C(OCC)NC1=CC=C(NCC2=CC=C(F)C=C2)N=C1N.O=C(O)/C=C\C(O)=O
Purity
>95% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
420.40
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Wörz R. [Long-term-treatment of chronic pain patients with flupirtine--on hepatotoxicity and persistent effectiveness from 7 months to 22 years]. MMW Fortschr Med. 2014 Dec 15;156 Suppl 4:127-34. Review. German. PubMed PMID: 26153592.
2: Szelenyi I. Flupirtine, a re-discovered drug, revisited. Inflamm Res. 2013 Mar;62(3):251-8. doi: 10.1007/s00011-013-0592-5. Epub 2013 Jan 16. Review. PubMed PMID: 23322112.
3: Raffa RB, Pergolizzi JV Jr. The evolving understanding of the analgesic mechanism of action of flupirtine. J Clin Pharm Ther. 2012 Feb;37(1):4-6. doi: 10.1111/j.1365-2710.2010.01233.x. Epub 2010 Nov 28. Review. PubMed PMID: 21114508.
4: Devulder J. Flupirtine in pain management: pharmacological properties and clinical use. CNS Drugs. 2010 Oct;24(10):867-81. doi: 10.2165/11536230-000000000-00000. Review. PubMed PMID: 20839897.
5: Klawe C, Maschke M. Flupirtine: pharmacology and clinical applications of a nonopioid analgesic and potentially neuroprotective compound. Expert Opin Pharmacother. 2009 Jun;10(9):1495-500. doi: 10.1517/14656560902988528. Review. PubMed PMID: 19505216.
6: Schröder HC, Müller WE. Neuroprotective effect of flupirtine in prion disease. Drugs Today (Barc). 2002 Jan;38(1):49-58. Review. PubMed PMID: 12532184.
7: Kornhuber J, Maler M, Wiltfang J, Bleich S, Degner D, Rüther E. [Neuronal potassium channel opening with flupirtine]. Fortschr Neurol Psychiatr. 1999 Oct;67(10):466-75. Review. German. PubMed PMID: 10596368.
8: Osborne NN, Cazevieille C, Wood JP, Nash MS, Pergande G, Block F, Kosinski C, Schwarz M. Flupirtine, a nonopioid centrally acting analgesic, acts as an NMDA antagonist. Gen Pharmacol. 1998 Mar;30(3):255-63. Review. PubMed PMID: 9510072.
9: Friedel HA, Fitton A. Flupirtine. A review of its pharmacological properties, and therapeutic efficacy in pain states. Drugs. 1993 Apr;45(4):548-69. Review. PubMed PMID: 7684675.
10: Riethmüller-Winzen H. Flupirtine in the treatment of post-operative pain. Postgrad Med J. 1987;63 Suppl 3:61-5. Review. PubMed PMID: 3328853.
